ORKA-001

Asset

Neutralizes IL-23 to inhibit inflammatory signaling.

Stage: Preclinical
Modality: Antibody
Target: IL23A; 2
Indications: 0
Trials: 1
Developer

Indications

2

Plaque psoriasis
Preclinical, sec.gov, Apr 3, 2024
Psoriatic arthritis
Preclinical, sec.gov, Apr 3, 2024

In the full profile

Targets and what it contains1
Owner and partners2
Evidence for its targets1
Competitors10
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.